成都倍特得诺

Chengdu Better Deno Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Chengdu, China, specializing in the development of innovative drugs for metabolic and cardiovascular diseases. The company was established as a strategic joint venture between Chengdu Better Pharmaceutical and Deno Therapeutics to combine large-scale manufacturing capabilities with advanced drug discovery. Its lead candidate, BTDN-001, is a dual GLP-1 and GIP receptor agonist currently undergoing clinical trials for the treatment of type 2 diabetes and obesity. Better Deno aims to address the growing global burden of metabolic disorders through the development of highly effective, long-acting peptide therapies. The company operates within the Chengdu Tianfu Bio-Town, benefiting from the region's robust life sciences ecosystem. By leveraging the commercial infrastructure of its parent company, Better Deno is well-positioned to bring next-generation metabolic treatments to the Chinese market.